Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

Figure 7

Prognostic value of the TNF family-based signature (TFS) for predicting 1-, 3-, and 5-year OS for CRC patients in the TCGA cohort. (a, b) The univariate and multivariate Cox regression analyses of the TFS and clinical factors. (c) Nomogram for predicting the 1-, 3- and 5-year OS based on the eight-gene TNF. (d–f) Calibration curves of the ability of the nomogram to predict 1-, 3- and 5-year OS.

(a)

(b)

(c)

(d)

(e)

(f)